FDA Determines Regulatory Review Period for NUWIQ Patent Extension

Summary

The Food and Drug Administration has published a notice determining the regulatory review period for NUWIQ, a human biological product, in response to a patent extension application submitted to the U.S. Patent and Trademark Office.